biotechnology

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program…

4 months ago

Vaxart Granted Extension by Nasdaq to Regain Compliance

August 29, 2025 08:00 ET  | Source: Vaxart, Inc. - Company must regain compliance with the Nasdaq Bid Price Rule…

4 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…

5 months ago

Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions

HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences…

5 months ago

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced…

5 months ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 17:06 ET  | Source: Taysha Gene Therapies, Inc. DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene…

5 months ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

July 08, 2025 21:36 ET  | Source: Cogent Biosciences, Inc. WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE)…

6 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

6 months ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to…

7 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

June 18, 2025 17:36 ET  | Source: Psyence Group Inc. TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc.…

7 months ago